MY172561A - Injectable antibiotic formulations and their methods of use - Google Patents
Injectable antibiotic formulations and their methods of useInfo
- Publication number
- MY172561A MY172561A MYPI2014703596A MYPI2014703596A MY172561A MY 172561 A MY172561 A MY 172561A MY PI2014703596 A MYPI2014703596 A MY PI2014703596A MY PI2014703596 A MYPI2014703596 A MY PI2014703596A MY 172561 A MY172561 A MY 172561A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- antibiotic formulations
- injectable antibiotic
- injectable
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ60129912 | 2012-07-17 | ||
| NZ61017513 | 2013-05-03 | ||
| NZ613138A NZ613138B2 (en) | 2013-07-12 | Injectable antibiotic formulations and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY172561A true MY172561A (en) | 2019-12-03 |
Family
ID=49949085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014703596A MY172561A (en) | 2012-07-17 | 2013-07-16 | Injectable antibiotic formulations and their methods of use |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10376585B2 (enExample) |
| EP (1) | EP2874624B8 (enExample) |
| JP (1) | JP6189437B2 (enExample) |
| KR (1) | KR102113822B1 (enExample) |
| CN (1) | CN104470517B (enExample) |
| AU (1) | AU2013290826B2 (enExample) |
| BR (1) | BR112014031083B1 (enExample) |
| CA (1) | CA2875351C (enExample) |
| CL (1) | CL2014003423A1 (enExample) |
| CO (1) | CO7240359A2 (enExample) |
| CR (1) | CR20140550A (enExample) |
| DK (1) | DK2874624T3 (enExample) |
| DO (1) | DOP2014000288A (enExample) |
| ES (1) | ES2752034T3 (enExample) |
| HR (1) | HRP20191730T1 (enExample) |
| HU (1) | HUE046427T2 (enExample) |
| IL (1) | IL236713B (enExample) |
| LT (1) | LT2874624T (enExample) |
| MX (2) | MX387668B (enExample) |
| MY (1) | MY172561A (enExample) |
| NI (1) | NI201400152A (enExample) |
| PH (1) | PH12014502716A1 (enExample) |
| PL (1) | PL2874624T3 (enExample) |
| PT (1) | PT2874624T (enExample) |
| RU (1) | RU2643327C2 (enExample) |
| SI (1) | SI2874624T1 (enExample) |
| SV (1) | SV2014004882A (enExample) |
| UA (1) | UA118654C2 (enExample) |
| WO (1) | WO2014014363A1 (enExample) |
| ZA (1) | ZA201409322B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014098624A1 (en) * | 2012-12-20 | 2014-06-26 | Alleva Animal Health Limited | Veterinary injectable formulations |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE49770B1 (en) | 1979-05-21 | 1985-12-11 | Leo Pharm Prod Ltd | 6beta-halopenicillanic acid derivatives |
| IE51516B1 (en) * | 1980-10-06 | 1987-01-07 | Leo Pharm Prod Ltd | 1,1-dioxapenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate napsylate |
| IL64009A (en) | 1980-10-31 | 1984-09-30 | Rech Applications Therap | Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them |
| IE51846B1 (en) * | 1980-11-17 | 1987-04-15 | Leo Pharm Prod Ltd | Pharmaceutical preparation for veterinary use and an appliance containing it |
| EP0115001B1 (de) | 1982-12-28 | 1988-06-15 | Bayer Ag | Stabile Aminoglykosid-Penicillin-Injektionsformulierungen |
| US5736151A (en) | 1996-12-09 | 1998-04-07 | Pharmacia & Upjohn Company | Antibiotic oil suspensions |
| CH693625A5 (it) * | 1999-02-18 | 2003-11-28 | Inpharma Sa | Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi. |
| US20040022815A1 (en) | 2002-08-05 | 2004-02-05 | Orchid Health Care | Novel pharmaceutical composition of ceftiofur |
| KR20040015622A (ko) | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물 |
| US6911441B2 (en) | 2002-12-16 | 2005-06-28 | Akzo Nobel N.V. | Prolonged release pharmaceutical composition |
| CN1517090A (zh) * | 2003-01-20 | 2004-08-04 | 王玉万 | 含抗菌药物的兽用混悬注射剂或乳剂 |
| US20050143347A1 (en) * | 2003-12-22 | 2005-06-30 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of accumulations of fat |
| DE102004025324A1 (de) * | 2004-05-19 | 2005-12-08 | Boehringer Ingelheim Vetmedica Gmbh | Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| US8679540B2 (en) * | 2006-06-09 | 2014-03-25 | Flamel Technologies | Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications |
| ES2716474T3 (es) * | 2007-10-26 | 2019-06-12 | Avivagen Inc | Composiciones y métodos para mejorar la respuesta inmunitaria |
| PL2294012T3 (pl) * | 2008-05-07 | 2014-12-31 | Salix Pharmaceuticals Inc | Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit |
| US8501800B2 (en) * | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| WO2010138918A1 (en) * | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
| CN101822637A (zh) * | 2009-12-31 | 2010-09-08 | 天津瑞普生物技术股份有限公司 | 一种含有β-内酰胺类抗生素的混悬注射剂 |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| DE102010015143A1 (de) | 2010-04-16 | 2011-10-20 | Cts Chemical Industries Ltd. | Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon |
| MX355769B (es) * | 2011-06-23 | 2018-04-30 | Bayer New Zealand Ltd | Una composición antiparasitaria y método de tratamiento. |
| WO2013095166A1 (en) | 2011-12-23 | 2013-06-27 | Bayer New Zealand Limited | Antibiotic formulations |
| CN110604819A (zh) * | 2012-02-27 | 2019-12-24 | 拜耳新西兰有限公司 | 控制释放组合物及其使用方法 |
-
2013
- 2013-07-16 JP JP2015523049A patent/JP6189437B2/ja active Active
- 2013-07-16 HR HRP20191730 patent/HRP20191730T1/hr unknown
- 2013-07-16 US US14/415,940 patent/US10376585B2/en active Active
- 2013-07-16 HU HUE13819728A patent/HUE046427T2/hu unknown
- 2013-07-16 UA UAA201501302A patent/UA118654C2/uk unknown
- 2013-07-16 CA CA2875351A patent/CA2875351C/en active Active
- 2013-07-16 DK DK13819728T patent/DK2874624T3/da active
- 2013-07-16 EP EP13819728.0A patent/EP2874624B8/en active Active
- 2013-07-16 MX MX2018009121A patent/MX387668B/es unknown
- 2013-07-16 PT PT138197280T patent/PT2874624T/pt unknown
- 2013-07-16 CN CN201380038000.4A patent/CN104470517B/zh active Active
- 2013-07-16 AU AU2013290826A patent/AU2013290826B2/en active Active
- 2013-07-16 ES ES13819728T patent/ES2752034T3/es active Active
- 2013-07-16 LT LT13819728T patent/LT2874624T/lt unknown
- 2013-07-16 RU RU2015105251A patent/RU2643327C2/ru active
- 2013-07-16 SI SI201331584T patent/SI2874624T1/sl unknown
- 2013-07-16 WO PCT/NZ2013/000123 patent/WO2014014363A1/en not_active Ceased
- 2013-07-16 MY MYPI2014703596A patent/MY172561A/en unknown
- 2013-07-16 PL PL13819728T patent/PL2874624T3/pl unknown
- 2013-07-16 KR KR1020157001143A patent/KR102113822B1/ko active Active
- 2013-07-16 BR BR112014031083-1A patent/BR112014031083B1/pt active IP Right Grant
- 2013-07-16 MX MX2014015927A patent/MX358248B/es active IP Right Grant
-
2014
- 2014-12-02 CR CR20140550A patent/CR20140550A/es unknown
- 2014-12-04 PH PH12014502716A patent/PH12014502716A1/en unknown
- 2014-12-17 CL CL2014003423A patent/CL2014003423A1/es unknown
- 2014-12-18 DO DO2014000288A patent/DOP2014000288A/es unknown
- 2014-12-18 ZA ZA2014/09322A patent/ZA201409322B/en unknown
- 2014-12-19 NI NI201400152A patent/NI201400152A/es unknown
- 2014-12-22 SV SV2014004882A patent/SV2014004882A/es unknown
- 2014-12-26 CO CO14284224A patent/CO7240359A2/es unknown
-
2015
- 2015-01-14 IL IL236713A patent/IL236713B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20180102A1 (ar) | مركب صيدلاني | |
| PH12014502602B1 (en) | Methods for improving safety of blood-brain barrier transport | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| GEP20196964B (en) | Pest control composition including novel iminopyridine derivative | |
| IN2014DN08481A (enExample) | ||
| IN2015DN00127A (enExample) | ||
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| IN2012MU03723A (enExample) | ||
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| MX2016001138A (es) | Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo. | |
| SI2939665T1 (sl) | Farmacevtska sestava za zdravljenje HIV infekcij | |
| IN2013MU03641A (enExample) | ||
| MX2015003034A (es) | Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso. | |
| UY34595A (es) | Composición farmacéutica de liberación prolongada de trimetazidina | |
| MX2014004210A (es) | Derivados de 2-oxo-piperidinilo. | |
| IN2014DN03010A (enExample) | ||
| UA110131C2 (ru) | ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ | |
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| EP3275457A4 (en) | Pharmaceutical composition containing silybin | |
| MX2012008253A (es) | Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida. | |
| PH12014502716A1 (en) | Injectable antibiotic formulations and their methods of use | |
| IN2012DE00826A (enExample) | ||
| MX338113B (es) | Proceso para la preparacion de polisulfonato de sodio del 5,14-dihidrotetraazapentaceno e intermediarios de los mismos. | |
| EP2884964A4 (en) | PHARMACEUTICAL COMPOSITION OF PROPOFOL |